Publications by authors named "E Du Rietz"
Article Synopsis
- * Both male and female schizophrenia patients faced higher risks of all-cause mortality, suicide, and natural causes, but no significant differences were found between the sexes in these risks.
- * Young females (<40) showed a notably higher mortality risk compared to older females, while males faced a much greater risk of dying from neurological disorders than females, indicating a need for better healthcare interventions.
Emerging evidence suggests that ADHD is associated with increased risk for metabolic and cardiovascular (cardiometabolic) diseases. However, an understanding of the mechanisms underlying these associations is still limited. In this study we estimated the associations of polygenic scores (PGS) for ADHD with several cardiometabolic diseases and biomarkers.
View Article and Find Full Text PDFArticle Synopsis
- Researchers studied how long-term use of ADHD medication affects the risk of developing type 2 diabetes (T2D) in a large group of people with ADHD in Sweden.
- The analysis showed that using ADHD medications for up to 3 years can actually reduce the risk of T2D, but long-term use of atomoxetine may increase the risk.
- Clinicians should keep an eye on potential diabetes risks, especially with prolonged atomoxetine use, but more research is needed to confirm these findings.
Introduction: People with severe mental illness have poor cardiometabolic health. Commonly used antidepressants and antipsychotics frequently lead to weight gain, which may further contribute to adverse cardiovascular outcomes.
Areas Covered: We searched MEDLINE up to April 2023 for umbrella reviews, (network-)meta-analyses, trials and cohort studies on risk factors, prevention and treatment strategies of weight gain associated with antidepressants/antipsychotics.
To further explore the role of different antipsychotic treatments for cardio-cerebrovascular mortality, we performed several subgroup, sensitivity and meta-regression analyses based on a large previous meta-analysis focusing on cohort studies assessing mortality relative risk (RR) for cardio-cerebrovascular disorders in people with schizophrenia, comparing antipsychotic treatment versus no antipsychotic. Quality assessment through the Newcastle-Ottawa Scale (NOS) and publication bias was measured. We meta-analyzed 53 different studies (schizophrenia patients: n = 2,513,359; controls: n = 360,504,484) to highlight the differential effects of antipsychotic treatment regimens on cardio-cerebrovascular-related mortality in incident and prevalent samples of patients with schizophrenia.
View Article and Find Full Text PDF